{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:40:25Z","timestamp":1793580025414,"version":"4.5.0"},"reference-count":179,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":60,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007195","name":"Universit\u00e0 degli Studi di Napoli Federico II","doi-asserted-by":"crossref","award":["FRA2022"],"award-info":[{"award-number":["FRA2022"]}],"id":[{"id":"10.13039\/100007195","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100020134","name":"Programma Operativo Nazionale Ricerca e Competitivit\u00e0","doi-asserted-by":"crossref","award":["E65F21002850007"],"award-info":[{"award-number":["E65F21002850007"]}],"id":[{"id":"10.13039\/501100020134","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"DOI":"10.1186\/s40164-026-00779-z","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T15:08:27Z","timestamp":1778512107000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Hierarchies of resistance to DNA damage response inhibitors: from pathway restoration to replication stress tolerance"],"prefix":"10.1186","volume":"15","author":[{"given":"Valentina","family":"Morgera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Feola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Vittoria","family":"Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Gabrielli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio Enrico","family":"Avvedimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Porcellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pezone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"issue":"7267","key":"779_CR1","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/nature08467","volume":"461","author":"SP Jackson","year":"2009","unstructured":"Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461(7267):1071\u20138. https:\/\/doi.org\/10.1038\/nature08467.","journal-title":"Nature"},{"issue":"2","key":"779_CR2","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.molcel.2010.09.019","volume":"40","author":"A Ciccia","year":"2010","unstructured":"Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell. 2010;40(2):179\u2013204. https:\/\/doi.org\/10.1016\/j.molcel.2010.09.019.","journal-title":"Mol Cell"},{"issue":"2","key":"779_CR3","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s12276-020-0384-2","volume":"52","author":"B Perillo","year":"2020","unstructured":"Perillo B, Di Donato M, Pezone A, Di Zazzo E, Giovannelli P, Galasso G, et al. ROS in cancer therapy: the bright side of the moon. Exp Mol Med. 2020;52(2):192\u2013203. https:\/\/doi.org\/10.1038\/s12276-020-0384-2.","journal-title":"Exp Mol Med"},{"issue":"1","key":"779_CR4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ncb2897","volume":"16","author":"MK Zeman","year":"2014","unstructured":"Zeman MK, Cimprich KA. Causes and consequences of replication stress. Nat Cell Biol. 2014;16(1):2\u20139. https:\/\/doi.org\/10.1038\/ncb2897.","journal-title":"Nat Cell Biol"},{"issue":"5","key":"779_CR5","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nrc3916","volume":"15","author":"H Gaillard","year":"2015","unstructured":"Gaillard H, Garc\u00eda-Muse T, Aguilera A. Replication stress and cancer. Nat Rev Cancer. 2015;15(5):276\u201389. https:\/\/doi.org\/10.1038\/nrc3916.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"779_CR6","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/j.cell.2016.09.053","volume":"167","author":"S Hamperl","year":"2016","unstructured":"Hamperl S, Cimprich KA. Conflict resolution in the genome: how transcription and replication make it work. Cell. 2016;167(6):1455\u201367. https:\/\/doi.org\/10.1016\/j.cell.2016.09.053.","journal-title":"Cell"},{"issue":"9","key":"779_CR7","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nrm.2016.88","volume":"17","author":"T Garc\u00eda-Muse","year":"2016","unstructured":"Garc\u00eda-Muse T, Aguilera A. Transcription\u2013replication conflicts: how they occur and how they are resolved. Nat Rev Mol Cell Biol. 2016;17(9):553\u201363. https:\/\/doi.org\/10.1038\/nrm.2016.88.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7119","key":"779_CR8","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/nature05327","volume":"444","author":"R Di Micco","year":"2006","unstructured":"Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature. 2006;444(7119):638\u201342. https:\/\/doi.org\/10.1038\/nature05327.","journal-title":"Nature"},{"issue":"7694","key":"779_CR9","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature25507","volume":"555","author":"M Macheret","year":"2018","unstructured":"Macheret M, Halazonetis TD. Intragenic origins due to short G1 phases underlie oncogene-induced DNA replication stress. Nature. 2018;555(7694):112\u20136. https:\/\/doi.org\/10.1038\/nature25507.","journal-title":"Nature"},{"issue":"4","key":"779_CR10","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","volume":"60","author":"MJ O\u2019Connor","year":"2015","unstructured":"O\u2019Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015;60(4):547\u201360. https:\/\/doi.org\/10.1016\/j.molcel.2015.10.040.","journal-title":"Mol Cell"},{"issue":"2","key":"779_CR11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","volume":"16","author":"PG Pili\u00e9","year":"2019","unstructured":"Pili\u00e9 PG, Tang C, Mills GB, Yap TA. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 2019;16(2):81\u2013104. https:\/\/doi.org\/10.1038\/s41571-018-0114-z.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"779_CR12","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.molcel.2017.05.001","volume":"66","author":"L Toledo","year":"2017","unstructured":"Toledo L, Neelsen KJ, Lukas J. Replication catastrophe: When a checkpoint fails because of exhaustion. Mol Cell. 2017;66(6):735\u201349. https:\/\/doi.org\/10.1016\/j.molcel.2017.05.001.","journal-title":"Mol Cell"},{"key":"779_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.564601","volume":"8","author":"M Rose","year":"2020","unstructured":"Rose M, Burgess JT, Byrne K, Richard DJ, Bolderson E. PARP inhibitors: Clinical relevance, mechanisms of action and tumor resistance. Front Cell Dev Biol. 2020;8:564601. https:\/\/doi.org\/10.3389\/fcell.2020.564601.","journal-title":"Front Cell Dev Biol"},{"issue":"6330","key":"779_CR14","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science. 2017;355(6330):1152\u20138. https:\/\/doi.org\/10.1126\/science.aam7344.","journal-title":"Science"},{"issue":"21","key":"779_CR15","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai J, Huang SyinN, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72(21):5588\u201399. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-2753.","journal-title":"Cancer Res"},{"issue":"1","key":"779_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01548-8","volume":"8","author":"Q Li","year":"2023","unstructured":"Li Q, Qian W, Zhang Y, Hu L, Chen S, Xia Y. A new wave of innovations within the DNA damage response. Signal Transduct Target Ther. 2023;8(1):338. https:\/\/doi.org\/10.1038\/s41392-023-01548-8.","journal-title":"Signal Transduct Target Ther"},{"key":"779_CR17","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2019.50","author":"A Mweempwa","year":"2019","unstructured":"Mweempwa A, Wilson MK. Mechanisms of resistance to PARP inhibitors\u2014an evolving challenge in oncology. Cancer Drug Resist. 2019. https:\/\/doi.org\/10.20517\/cdr.2019.50.","journal-title":"Cancer Drug Resist"},{"issue":"14","key":"779_CR18","doi-asserted-by":"publisher","first-page":"1354427","DOI":"10.3389\/fonc.2024.1354427","volume":"13","author":"L Collet","year":"2024","unstructured":"Collet L, Hanvic B, Turinetto M, Treilleux I, Chopin N, Le Saux O, et al. BRCA1\/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challenges. Front Oncol. 2024;13(14):1354427. https:\/\/doi.org\/10.3389\/fonc.2024.1354427.","journal-title":"Front Oncol"},{"key":"779_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2018.09.003","volume":"71","author":"B Haynes","year":"2018","unstructured":"Haynes B, Murai J, Lee JM. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition. Cancer Treat Rev. 2018;71:1\u20137. https:\/\/doi.org\/10.1016\/j.ctrv.2018.09.003.","journal-title":"Cancer Treat Rev"},{"issue":"21","key":"779_CR20","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1007\/s00018-013-1307-3","volume":"70","author":"M Patil","year":"2013","unstructured":"Patil M, Pabla N, Dong Z. Checkpoint kinase 1 in DNA damage response and cell cycle regulation. Cell Mol Life Sci. 2013;70(21):4009\u201321. https:\/\/doi.org\/10.1007\/s00018-013-1307-3.","journal-title":"Cell Mol Life Sci"},{"issue":"7","key":"779_CR21","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.7150\/ijbs.72534","volume":"18","author":"A Zhang","year":"2022","unstructured":"Zhang A, Miao K, Sun H, Deng CX. Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance. Int J Biol Sci. 2022;18(7):3019\u201333. https:\/\/doi.org\/10.7150\/ijbs.72534.","journal-title":"Int J Biol Sci"},{"issue":"6","key":"779_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ph18060915","volume":"18","author":"S Tonello","year":"2025","unstructured":"Tonello S, Rolla R, Tillio PA, Sainaghi PP, Colangelo D. Microenvironment and tumor heterogeneity as pharmacological targets in precision oncology. Pharmaceuticals. 2025;18(6):915. https:\/\/doi.org\/10.3390\/ph18060915.","journal-title":"Pharmaceuticals"},{"issue":"14","key":"779_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143642","volume":"15","author":"S Dilmac","year":"2023","unstructured":"Dilmac S, Ozpolat B. Mechanisms of PARP-inhibitor-resistance in BRCA-mutated breast cancer and new therapeutic approaches. Cancers. 2023;15(14):3642. https:\/\/doi.org\/10.3390\/cancers15143642.","journal-title":"Cancers"},{"issue":"46","key":"779_CR24","doi-asserted-by":"publisher","first-page":"5020","DOI":"10.1038\/s41388-022-02491-8","volume":"41","author":"TT Huang","year":"2022","unstructured":"Huang TT, Burkett SS, Tandon M, Yamamoto TM, Gupta N, Bitler BG, et al. Distinct roles of treatment schemes and BRCA2 on the restoration of homologous recombination DNA repair and PARP inhibitor resistance in ovarian cancer. Oncogene. 2022;41(46):5020\u201331. https:\/\/doi.org\/10.1038\/s41388-022-02491-8.","journal-title":"Oncogene"},{"issue":"4","key":"779_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/narcan\/zcac042","volume":"4","author":"LM Jackson","year":"2022","unstructured":"Jackson LM, Moldovan GL. Mechanisms of PARP1 inhibitor resistance and their implications for cancer treatment. NAR Cancer. 2022;4(4):zcac042. https:\/\/doi.org\/10.1093\/narcan\/zcac042.","journal-title":"NAR Cancer"},{"issue":"15","key":"779_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2021.07.015","volume":"81","author":"K Cong","year":"2021","unstructured":"Cong K, Peng M, Kousholt AN, Lee WTC, Lee S, Nayak S, et al. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency. Mol Cell. 2021;81(15):3227. https:\/\/doi.org\/10.1016\/j.molcel.2021.07.015.","journal-title":"Mol Cell"},{"issue":"17\u201318","key":"779_CR27","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1101\/gad.348479.121","volume":"35","author":"A Simoneau","year":"2021","unstructured":"Simoneau A, Xiong R, Zou L. The trans cell cycle effects of PARP inhibitors underlie their selectivity toward BRCA1\/2-deficient cells. Genes Dev. 2021;35(17\u201318):1271\u201389. https:\/\/doi.org\/10.1101\/gad.348479.121.","journal-title":"Genes Dev"},{"issue":"1\u20132","key":"779_CR28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1053\/j.seminoncol.2023.08.001","volume":"51","author":"PB Kanev","year":"2024","unstructured":"Kanev PB, Atemin A, Stoynov S, Aleksandrov R. PARP1 roles in DNA repair and DNA replication: the basi(c)s of PARP inhibitor efficacy and resistance. Semin Oncol. 2024;51(1\u20132):2\u201318. https:\/\/doi.org\/10.1053\/j.seminoncol.2023.08.001.","journal-title":"Semin Oncol"},{"issue":"7713","key":"779_CR29","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41586-018-0261-5","volume":"559","author":"A Maya-Mendoza","year":"2018","unstructured":"Maya-Mendoza A, Moudry P, Merchut-Maya JM, Lee M, Strauss R, Bartek J. High speed of fork progression induces DNA replication stress and genomic instability. Nature. 2018;559(7713):279\u201384. https:\/\/doi.org\/10.1038\/s41586-018-0261-5.","journal-title":"Nature"},{"issue":"17","key":"779_CR30","doi-asserted-by":"publisher","first-page":"9694","DOI":"10.1093\/nar\/gkaa718","volume":"48","author":"Z Shao","year":"2020","unstructured":"Shao Z, Lee BJ, Rouleau-Turcotte \u00c9, Langelier MF, Lin X, Estes VM, et al. Clinical PARP inhibitors do not abrogate PARP1 exchange at DNA damage sites in vivo. Nucleic Acids Res. 2020;48(17):9694\u2013709. https:\/\/doi.org\/10.1093\/nar\/gkaa718.","journal-title":"Nucleic Acids Res"},{"key":"779_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2025.103842","volume":"86","author":"A Romano","year":"2025","unstructured":"Romano A, Feola A, Morgera V, Tramontano A, Messina S, Gackowski D, et al. Strand-specific quantification of 8-oxo-dG and apurinic sites via ligation-dependent probe amplification (LPA). Redox Biol. 2025;86:103842. https:\/\/doi.org\/10.1016\/j.redox.2025.103842.","journal-title":"Redox Biol"},{"issue":"21","key":"779_CR32","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.1002\/1878-0261.13224","volume":"16","author":"JS Baxter","year":"2022","unstructured":"Baxter JS, Zatreanu D, Pettitt SJ, Lord CJ. Resistance to DNA repair inhibitors in cancer. Mol Oncol. 2022;16(21):3811\u201327. https:\/\/doi.org\/10.1002\/1878-0261.13224.","journal-title":"Mol Oncol"},{"issue":"10","key":"779_CR33","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1158\/2159-8290.CD-19-1485","volume":"10","author":"SJ Pettitt","year":"2020","unstructured":"Pettitt SJ, Frankum JR, Punta M, Lise S, Alexander J, Chen Y, et al. Clinical BRCA1\/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance. Cancer Discov. 2020;10(10):1475\u201388. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-1485.","journal-title":"Cancer Discov"},{"issue":"1","key":"779_CR34","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.annonc.2020.10.470","volume":"32","author":"L Tobalina","year":"2021","unstructured":"Tobalina L, Armenia J, Irving E, O\u2019Connor MJ, Forment JV. A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance. Ann Oncol. 2021;32(1):103\u201312. https:\/\/doi.org\/10.1016\/j.annonc.2020.10.470.","journal-title":"Ann Oncol"},{"issue":"7716","key":"779_CR35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41586-018-0340-7","volume":"560","author":"SM Noordermeer","year":"2018","unstructured":"Noordermeer SM, Adam S, Setiaputra D, Barazas M, Pettitt SJ, Ling AK, et al. The shieldin complex mediates 53BP1-dependent DNA repair. Nature. 2018;560(7716):117\u201321. https:\/\/doi.org\/10.1038\/s41586-018-0340-7.","journal-title":"Nature"},{"issue":"8","key":"779_CR36","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41556-018-0140-1","volume":"20","author":"H Dev","year":"2018","unstructured":"Dev H, Chiang TWW, Lescale C, De Krijger I, Martin AG, Pilger D, et al. Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells. Nat Cell Biol. 2018;20(8):954\u201365. https:\/\/doi.org\/10.1038\/s41556-018-0140-1.","journal-title":"Nat Cell Biol"},{"issue":"11","key":"779_CR37","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/ncb3626","volume":"19","author":"B Rondinelli","year":"2017","unstructured":"Rondinelli B, Gogola E, Y\u00fccel H, Duarte AA, Van De Ven M, Van Der Sluijs R, et al. EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation. Nat Cell Biol. 2017;19(11):1371\u20138. https:\/\/doi.org\/10.1038\/ncb3626.","journal-title":"Nat Cell Biol"},{"issue":"2","key":"779_CR38","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.molcel.2020.08.018","volume":"80","author":"JJ Kim","year":"2020","unstructured":"Kim JJ, Lee SY, Choi JH, Woo HG, Xhemalce B, Miller KM. PCAF-mediated histone acetylation promotes replication fork degradation by MRE11 and EXO1 in BRCA-deficient cells. Mol Cell. 2020;80(2):327-344.e8. https:\/\/doi.org\/10.1016\/j.molcel.2020.08.018.","journal-title":"Mol Cell"},{"issue":"1","key":"779_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34109-8","volume":"13","author":"YR Murciano-Goroff","year":"2022","unstructured":"Murciano-Goroff YR, Schram AM, Rosen EY, Won H, Gong Y, Noronha AM, et al. Reversion mutations in germline BRCA1\/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies. Nat Commun. 2022;13(1):7182. https:\/\/doi.org\/10.1038\/s41467-022-34109-8.","journal-title":"Nat Commun"},{"issue":"5","key":"779_CR40","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.annonc.2020.02.008","volume":"31","author":"AG Waks","year":"2020","unstructured":"Waks AG, Cohen O, Kochupurakkal B, Kim D, Dunn CE, Buendia Buendia J, et al. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1\/2-mutant metastatic breast cancer. Ann Oncol. 2020;31(5):590\u20138. https:\/\/doi.org\/10.1016\/j.annonc.2020.02.008.","journal-title":"Ann Oncol"},{"issue":"10","key":"779_CR41","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.tcb.2019.07.008","volume":"29","author":"SM Noordermeer","year":"2019","unstructured":"Noordermeer SM, Van Attikum H. PARP inhibitor resistance: a tug-of-war in BRCA-mutated cells. Trends Cell Biol. 2019;29(10):820\u201334. https:\/\/doi.org\/10.1016\/j.tcb.2019.07.008.","journal-title":"Trends Cell Biol"},{"issue":"7553","key":"779_CR42","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nature14328","volume":"521","author":"G Xu","year":"2015","unstructured":"Xu G, Chapman JR, Brandsma I, Yuan J, Mistrik M, Bouwman P, et al. REV7 counteracts DNA double-strand break resection and affects PARP inhibition. Nature. 2015;521(7553):541\u20134. https:\/\/doi.org\/10.1038\/nature14328.","journal-title":"Nature"},{"issue":"1","key":"779_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01164-5","volume":"8","author":"S Mijic","year":"2017","unstructured":"Mijic S, Zellweger R, Chappidi N, Berti M, Jacobs K, Mutreja K, et al. Replication fork reversal triggers fork degradation in BRCA2-defective cells. Nat Commun. 2017;8(1):859. https:\/\/doi.org\/10.1038\/s41467-017-01164-5.","journal-title":"Nat Commun"},{"issue":"1","key":"779_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-018-0612-8","volume":"10","author":"P Francica","year":"2018","unstructured":"Francica P, Rottenberg S. Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response. Genome Med. 2018;10(1):101. https:\/\/doi.org\/10.1186\/s13073-018-0612-8.","journal-title":"Genome Med"},{"issue":"1","key":"779_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03917-2","volume":"9","author":"SJ Pettitt","year":"2018","unstructured":"Pettitt SJ, Krastev DB, Brandsma I, Dr\u00e9an A, Song F, Aleksandrov R, et al. Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. Nat Commun. 2018;9(1):1849. https:\/\/doi.org\/10.1038\/s41467-018-03917-2.","journal-title":"Nat Commun"},{"issue":"9","key":"779_CR46","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1158\/2159-8290.CD-17-0419","volume":"7","author":"O Kondrashova","year":"2017","unstructured":"Kondrashova O, Nguyen M, Shield-Artin K, Tinker AV, Teng NNH, Harrell MI, et al. Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor Rucaparib in high-grade ovarian carcinoma. Cancer Discov. 2017;7(9):984\u201398. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0419.","journal-title":"Cancer Discov"},{"issue":"5","key":"779_CR47","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1093\/annonc\/mdy099","volume":"29","author":"C Cruz","year":"2018","unstructured":"Cruz C, Castroviejo-Bermejo M, Guti\u00e9rrez-Enr\u00edquez S, Llop-Guevara A, Ibrahim YH, Gris-Oliver A, et al. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Ann Oncol. 2018;29(5):1203\u201310. https:\/\/doi.org\/10.1093\/annonc\/mdy099.","journal-title":"Ann Oncol"},{"issue":"2","key":"779_CR48","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","volume":"9","author":"KK Lin","year":"2019","unstructured":"Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, et al. BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor Rucaparib in high-grade ovarian carcinoma. Cancer Discov. 2019;9(2):210\u20139. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0715.","journal-title":"Cancer Discov"},{"issue":"9","key":"779_CR49","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1158\/2159-8290.CD-17-0146","volume":"7","author":"D Quigley","year":"2017","unstructured":"Quigley D, Alumkal JJ, Wyatt AW, Kothari V, Foye A, Lloyd P, et al. Analysis of circulating cell-free DNA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors. Cancer Discov. 2017;7(9):999\u20131005. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0146.","journal-title":"Cancer Discov"},{"issue":"5","key":"779_CR50","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201847560","volume":"20","author":"D Setiaputra","year":"2019","unstructured":"Setiaputra D, Durocher D. Shieldin\u2014the protector of DNA ends. EMBO Rep. 2019;20(5):e47560. https:\/\/doi.org\/10.15252\/embr.201847560.","journal-title":"EMBO Rep"},{"issue":"4","key":"779_CR51","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.cell.2018.03.050","volume":"173","author":"R Gupta","year":"2018","unstructured":"Gupta R, Somyajit K, Narita T, Maskey E, Stanlie A, Kremer M, et al. DNA repair network analysis reveals Shieldin as a key regulator of NHEJ and PARP inhibitor sensitivity. Cell. 2018;173(4):972-988.e23. https:\/\/doi.org\/10.1016\/j.cell.2018.03.050.","journal-title":"Cell"},{"issue":"2","key":"779_CR52","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1039\/C6MD00439C","volume":"8","author":"C Ronco","year":"2017","unstructured":"Ronco C, Martin AR, Demange L, Benhida R. ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells. MedChemComm. 2017;8(2):295\u2013319. https:\/\/doi.org\/10.1039\/C6MD00439C.","journal-title":"MedChemComm"},{"issue":"3","key":"779_CR53","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.molcel.2020.10.008","volume":"80","author":"F Li","year":"2020","unstructured":"Li F, Kozono D, Deraska P, Branigan T, Dunn C, Zheng XF, et al. CHK1 inhibitor blocks phosphorylation of FAM122A and promotes replication stress. Mol Cell. 2020;80(3):410-422.e6. https:\/\/doi.org\/10.1016\/j.molcel.2020.10.008.","journal-title":"Mol Cell"},{"issue":"3","key":"779_CR54","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1101\/gad.290957.116","volume":"31","author":"SA Yazinski","year":"2017","unstructured":"Yazinski SA, Comaills V, Buisson R, Genois MM, Nguyen HD, Ho CK, et al. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes Dev. 2017;31(3):318\u201332. https:\/\/doi.org\/10.1101\/gad.290957.116.","journal-title":"Genes Dev"},{"issue":"7612","key":"779_CR55","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nature18325","volume":"535","author":"A Ray Chaudhuri","year":"2016","unstructured":"Ray Chaudhuri A, Callen E, Ding X, Gogola E, Duarte AA, Lee JE, et al. Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature. 2016;535(7612):382\u20137. https:\/\/doi.org\/10.1038\/nature18325.","journal-title":"Nature"},{"issue":"2","key":"779_CR56","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2019103654","volume":"40","author":"X Lyu","year":"2021","unstructured":"Lyu X, Lei K, Biak Sang P, Shiva O, Chastain M, Chi P, et al. Human CST complex protects stalled replication forks by directly blocking MRE11 degradation of nascent\u2010strand DNA. EMBO J. 2021;40(2):e103654. https:\/\/doi.org\/10.15252\/embj.2019103654.","journal-title":"EMBO J"},{"issue":"1","key":"779_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15983","volume":"8","author":"X Lai","year":"2017","unstructured":"Lai X, Broderick R, Bergoglio V, Zimmer J, Badie S, Niedzwiedz W, et al. MUS81 nuclease activity is essential for replication stress tolerance and chromosome segregation in BRCA2-deficient cells. Nat Commun. 2017;8(1):15983. https:\/\/doi.org\/10.1038\/ncomms15983.","journal-title":"Nat Commun"},{"issue":"5","key":"779_CR58","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.molcel.2017.11.022","volume":"68","author":"A Quinet","year":"2017","unstructured":"Quinet A, Lema\u00e7on D, Vindigni A. Replication fork reversal: players and guardians. Mol Cell. 2017;68(5):830\u20133. https:\/\/doi.org\/10.1016\/j.molcel.2017.11.022.","journal-title":"Mol Cell"},{"issue":"1","key":"779_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11246-1","volume":"10","author":"C Mukherjee","year":"2019","unstructured":"Mukherjee C, Tripathi V, Manolika EM, Heijink AM, Ricci G, Merzouk S, et al. RIF1 promotes replication fork protection and efficient restart to maintain genome stability. Nat Commun. 2019;10(1):3287. https:\/\/doi.org\/10.1038\/s41467-019-11246-1.","journal-title":"Nat Commun"},{"issue":"1","key":"779_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32861-5","volume":"13","author":"I Paniagua","year":"2022","unstructured":"Paniagua I, Tayeh Z, Falcone M, Hern\u00e1ndez P\u00e9rez S, Cerutti A, Jacobs JJL. MAD2L2 promotes replication fork protection and recovery in a shieldin-independent and REV3L-dependent manner. Nat Commun. 2022;13(1):5167. https:\/\/doi.org\/10.1038\/s41467-022-32861-5.","journal-title":"Nat Commun"},{"issue":"11","key":"779_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25112496","volume":"25","author":"P Karakaidos","year":"2020","unstructured":"Karakaidos P, Karagiannis D, Rampias T. Resolving DNA damage: epigenetic regulation of DNA repair. Molecules. 2020;25(11):2496. https:\/\/doi.org\/10.3390\/molecules25112496.","journal-title":"Molecules"},{"issue":"1","key":"779_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-64445-4","volume":"16","author":"CD Rouault","year":"2025","unstructured":"Rouault CD, Charafe-Jauffret E, Ginestier C. The interplay of DNA damage, epigenetics and tumour heterogeneity in driving cancer cell fitness. Nat Commun. 2025;16(1):8733. https:\/\/doi.org\/10.1038\/s41467-025-64445-4.","journal-title":"Nat Commun"},{"issue":"1","key":"779_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/srep33222","volume":"6","author":"G Russo","year":"2016","unstructured":"Russo G, Landi R, Pezone A, Morano A, Zuchegna C, Romano A, et al. DNA damage and repair modify DNA methylation and chromatin domain of the targeted locus: mechanism of allele methylation polymorphism. Sci Rep. 2016;6(1):33222. https:\/\/doi.org\/10.1038\/srep33222.","journal-title":"Sci Rep"},{"issue":"1","key":"779_CR64","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/GCO.0000000000000600","volume":"32","author":"K Kubalanza","year":"2020","unstructured":"Kubalanza K, Konecny GE. Mechanisms of PARP inhibitor resistance in ovarian cancer. Curr Opin Obstet Gynecol. 2020;32(1):36\u201341. https:\/\/doi.org\/10.1097\/GCO.0000000000000600.","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"4","key":"779_CR65","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/j.gendis.2022.04.002","volume":"10","author":"H Song","year":"2023","unstructured":"Song H, Shen R, Liu X, Yang X, Xie K, Guo Z, et al. Histone post-translational modification and the DNA damage response. Genes Dis. 2023;10(4):1429\u201344. https:\/\/doi.org\/10.1016\/j.gendis.2022.04.002.","journal-title":"Genes Dis"},{"key":"779_CR66","doi-asserted-by":"publisher","DOI":"10.1095\/biolreprod.115.134924","author":"Q Yang","year":"2016","unstructured":"Yang Q, Nair S, Laknaur A, Ismail N, Diamond MP, Al-Hendy A. The polycomb group protein EZH2 impairs DNA damage repair gene expression in human uterine fibroids1. Biol Reprod. 2016. https:\/\/doi.org\/10.1095\/biolreprod.115.134924.","journal-title":"Biol Reprod"},{"issue":"2","key":"779_CR67","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ccell.2019.12.015","volume":"37","author":"S Karakashev","year":"2020","unstructured":"Karakashev S, Fukumoto T, Zhao B, Lin J, Wu S, Fatkhutdinov N, et al. EZH2 inhibition sensitizes CARM1-high, homologous recombination proficient ovarian cancers to PARP inhibition. Cancer Cell. 2020;37(2):157-167.e6. https:\/\/doi.org\/10.1016\/j.ccell.2019.12.015.","journal-title":"Cancer Cell"},{"issue":"7","key":"779_CR68","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1158\/2159-8290.CD-14-0849","volume":"5","author":"J Shen","year":"2015","unstructured":"Shen J, Peng Y, Wei L, Zhang W, Yang L, Lan L, et al. ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors. Cancer Discov. 2015;5(7):752\u201367. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0849.","journal-title":"Cancer Discov"},{"issue":"1","key":"779_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13837","volume":"7","author":"CT Williamson","year":"2016","unstructured":"Williamson CT, Miller R, Pemberton HN, Jones SE, Campbell J, Konde A, et al. ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. Nat Commun. 2016;7(1):13837. https:\/\/doi.org\/10.1038\/ncomms13837.","journal-title":"Nat Commun"},{"issue":"1","key":"779_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42850-x","volume":"14","author":"L Tao","year":"2023","unstructured":"Tao L, Zhou Y, Pan X, Luo Y, Qiu J, Zhou X, et al. Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1\/2 and RAD51. Nat Commun. 2023;14(1):7430. https:\/\/doi.org\/10.1038\/s41467-023-42850-x.","journal-title":"Nat Commun"},{"issue":"12","key":"779_CR71","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1038\/s12276-020-00542-2","volume":"52","author":"B Perillo","year":"2020","unstructured":"Perillo B, Tramontano A, Pezone A, Migliaccio A. LSD1: more than demethylation of histone lysine residues. Exp Mol Med. 2020;52(12):1936\u201347. https:\/\/doi.org\/10.1038\/s12276-020-00542-2.","journal-title":"Exp Mol Med"},{"issue":"16","key":"779_CR72","doi-asserted-by":"publisher","first-page":"8943","DOI":"10.1093\/nar\/gkaa599","volume":"48","author":"A Pezone","year":"2020","unstructured":"Pezone A, Taddei ML, Tramontano A, Dolcini J, Boffo FL, De Rosa M, et al. Targeted DNA oxidation by LSD1\u2013SMAD2\/3 primes TGF-\u03b21\/ EMT genes for activation or repression. Nucleic Acids Res. 2020;48(16):8943\u201358. https:\/\/doi.org\/10.1093\/nar\/gkaa599.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"779_CR73","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.molcel.2016.05.029","volume":"62","author":"JP Etchegaray","year":"2016","unstructured":"Etchegaray JP, Mostoslavsky R. Interplay between metabolism and epigenetics: a nuclear adaptation to environmental changes. Mol Cell. 2016;62(5):695\u2013711. https:\/\/doi.org\/10.1016\/j.molcel.2016.05.029.","journal-title":"Mol Cell"},{"issue":"12","key":"779_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24129951","volume":"24","author":"T Improda","year":"2023","unstructured":"Improda T, Morgera V, Vitale M, Chiariotti L, Passaro F, Feola A, et al. Specific Methyl-CpG configurations define cell identity through gene expression regulation. Int J Mol Sci. 2023;24(12):9951. https:\/\/doi.org\/10.3390\/ijms24129951.","journal-title":"Int J Mol Sci"},{"key":"779_CR75","doi-asserted-by":"publisher","first-page":"5925","DOI":"10.1016\/j.csbj.2022.10.027","volume":"20","author":"A Sarnataro","year":"2022","unstructured":"Sarnataro A, De Riso G, Cocozza S, Pezone A, Majello B, Amente S, et al. A novel workflow for the qualitative analysis of DNA methylation data. Comput Struct Biotechnol J. 2022;20:5925\u201334. https:\/\/doi.org\/10.1016\/j.csbj.2022.10.027.","journal-title":"Comput Struct Biotechnol J"},{"issue":"8","key":"779_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081800","volume":"13","author":"G Russo","year":"2021","unstructured":"Russo G, Tramontano A, Iodice I, Chiariotti L, Pezone A. Epigenome chaos: stochastic and deterministic DNA methylation events drive cancer evolution. Cancers. 2021;13(8):1800. https:\/\/doi.org\/10.3390\/cancers13081800.","journal-title":"Cancers"},{"issue":"4","key":"779_CR77","doi-asserted-by":"publisher","DOI":"10.1093\/nargab\/lqaa096","volume":"2","author":"A Pezone","year":"2020","unstructured":"Pezone A, Tramontano A, Scala G, Cuomo M, Riccio P, De Nicola S, et al. Tracing and tracking epiallele families in complex DNA populations. NAR Genom Bioinform. 2020;2(4):lqaa096. https:\/\/doi.org\/10.1093\/nargab\/lqaa096.","journal-title":"NAR Genom Bioinform"},{"issue":"3","key":"779_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/biom10030446","volume":"10","author":"A Tramontano","year":"2020","unstructured":"Tramontano A, Boffo FL, Russo G, De Rosa M, Iodice I, Pezone A. Methylation of the suppressor gene p16INK4a: mechanism and consequences. Biomolecules. 2020;10(3):446. https:\/\/doi.org\/10.3390\/biom10030446.","journal-title":"Biomolecules"},{"issue":"25","key":"779_CR79","doi-asserted-by":"publisher","first-page":"40359","DOI":"10.18632\/oncotarget.16122","volume":"8","author":"B Allen","year":"2017","unstructured":"Allen B, Pezone A, Porcellini A, Muller MT, Masternak MM. Non-homologous end joining induced alterations in DNA methylation: a source of permanent epigenetic change. Oncotarget. 2017;8(25):40359\u201372. https:\/\/doi.org\/10.18632\/oncotarget.16122.","journal-title":"Oncotarget"},{"issue":"1","key":"779_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05564-z","volume":"9","author":"O Kondrashova","year":"2018","unstructured":"Kondrashova O, Topp M, Nesic K, Lieschke E, Ho GY, Harrell MI, et al. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun. 2018;9(1):3970. https:\/\/doi.org\/10.1038\/s41467-018-05564-z.","journal-title":"Nat Commun"},{"issue":"1","key":"779_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2017.43","volume":"4","author":"A Pezone","year":"2017","unstructured":"Pezone A, Russo G, Tramontano A, Florio E, Scala G, Landi R, et al. High-coverage methylation data of a gene model before and after DNA damage and homologous repair. Sci Data. 2017;4(1):170043. https:\/\/doi.org\/10.1038\/sdata.2017.43.","journal-title":"Sci Data"},{"issue":"1","key":"779_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22582-6","volume":"12","author":"EM Swisher","year":"2021","unstructured":"Swisher EM, Kwan TT, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, et al. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nat Commun. 2021;12(1):2487. https:\/\/doi.org\/10.1038\/s41467-021-22582-6.","journal-title":"Nat Commun"},{"key":"779_CR83","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.mam.2016.09.001","volume":"54","author":"X Gao","year":"2017","unstructured":"Gao X, Reid MA, Kong M, Locasale JW. Metabolic interactions with cancer epigenetics. Mol Aspects Med. 2017;54:50\u20137. https:\/\/doi.org\/10.1016\/j.mam.2016.09.001.","journal-title":"Mol Aspects Med"},{"issue":"14","key":"779_CR84","doi-asserted-by":"publisher","first-page":"5408","DOI":"10.1074\/jbc.TM118.000831","volume":"294","author":"KA Tran","year":"2019","unstructured":"Tran KA, Dillingham CM, Sridharan R. The role of \u03b1-ketoglutarate\u2013dependent proteins in pluripotency acquisition and maintenance. J Biol Chem. 2019;294(14):5408\u201319. https:\/\/doi.org\/10.1074\/jbc.TM118.000831.","journal-title":"J Biol Chem"},{"issue":"10","key":"779_CR85","doi-asserted-by":"publisher","DOI":"10.3390\/genes12101475","volume":"12","author":"A Shaw","year":"2021","unstructured":"Shaw A, Gullerova M. Home and away: the role of non-coding RNA in intracellular and intercellular DNA damage response. Genes. 2021;12(10):1475. https:\/\/doi.org\/10.3390\/genes12101475.","journal-title":"Genes"},{"issue":"5","key":"779_CR86","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/abbs\/gmy022","volume":"50","author":"M Su","year":"2018","unstructured":"Su M, Wang H, Wang W, Wang Y, Ouyang L, Pan C, et al. LncRNAs in DNA damage response and repair in cancer cells. Acta Biochim Biophys Sin. 2018;50(5):433\u20139. https:\/\/doi.org\/10.1093\/abbs\/gmy022.","journal-title":"Acta Biochim Biophys Sin"},{"issue":"1","key":"779_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24236-z","volume":"12","author":"MM Lou","year":"2021","unstructured":"Lou MM, Tang XQ, Wang GM, He J, Luo F, Guan MF, et al. Long noncoding RNA BS-DRL1 modulates the DNA damage response and genome stability by interacting with HMGB1 in neurons. Nat Commun. 2021;12(1):4075. https:\/\/doi.org\/10.1038\/s41467-021-24236-z.","journal-title":"Nat Commun"},{"issue":"1","key":"779_CR88","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02355-1","volume":"24","author":"Y Zou","year":"2025","unstructured":"Zou Y, Zhang H, Chen P, Tang J, Yang S, Nicot C, et al. Clinical approaches to overcome PARP inhibitor resistance. Mol Cancer. 2025;24(1):156. https:\/\/doi.org\/10.1186\/s12943-025-02355-1.","journal-title":"Mol Cancer"},{"issue":"8","key":"779_CR89","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1136\/ijgc-2020-001277","volume":"30","author":"NY Ngoi","year":"2020","unstructured":"Ngoi NY, Sundararajan V, Tan DS. Exploiting replicative stress in gynecological cancers as a therapeutic strategy. Int J Gynecol Cancer. 2020;30(8):1224\u201338. https:\/\/doi.org\/10.1136\/ijgc-2020-001277.","journal-title":"Int J Gynecol Cancer"},{"issue":"8","key":"779_CR90","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1038\/s41556-022-00965-1","volume":"24","author":"FF Diehl","year":"2022","unstructured":"Diehl FF, Miettinen TP, Elbashir R, Nabel CS, Darnell AM, Do BT, et al. Nucleotide imbalance decouples cell growth from cell proliferation. Nat Cell Biol. 2022;24(8):1252\u201364. https:\/\/doi.org\/10.1038\/s41556-022-00965-1.","journal-title":"Nat Cell Biol"},{"issue":"5","key":"779_CR91","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41568-023-00557-7","volume":"23","author":"NJ Mullen","year":"2023","unstructured":"Mullen NJ, Singh PK. Nucleotide metabolism: a pan-cancer metabolic dependency. Nat Rev Cancer. 2023;23(5):275\u201394. https:\/\/doi.org\/10.1038\/s41568-023-00557-7.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"779_CR92","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00354-w","volume":"6","author":"LE Navas","year":"2021","unstructured":"Navas LE, Carnero A. NAD+ metabolism, stemness, the immune response, and cancer. Signal Transduct Target Ther. 2021;6(1):2. https:\/\/doi.org\/10.1038\/s41392-020-00354-w.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"779_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13398","volume":"7","author":"RD Rasmussen","year":"2016","unstructured":"Rasmussen RD, Gajjar MK, Tuckova L, Jensen KE, Maya-Mendoza A, Holst CB, et al. BRCA1-regulated RRM2 expression protects glioblastoma cells from endogenous replication stress and promotes tumorigenicity. Nat Commun. 2016;7(1):13398. https:\/\/doi.org\/10.1038\/ncomms13398.","journal-title":"Nat Commun"},{"issue":"3","key":"779_CR94","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.ccell.2019.02.004","volume":"35","author":"N Pillay","year":"2019","unstructured":"Pillay N, Tighe A, Nelson L, Littler S, Coulson-Gilmer C, Bah N, et al. DNA replication vulnerabilities render Ovarian Cancer cells sensitive to Poly(ADP-Ribose) glycohydrolase inhibitors. Cancer Cell. 2019;35(3):519-533.e8. https:\/\/doi.org\/10.1016\/j.ccell.2019.02.004.","journal-title":"Cancer Cell"},{"issue":"2","key":"779_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.110236","volume":"38","author":"ER Abt","year":"2022","unstructured":"Abt ER, Le TM, Dann AM, Capri JR, Poddar S, Lok V, et al. Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in pancreatic cancer cells. Cell Rep. 2022;38(2):110236. https:\/\/doi.org\/10.1016\/j.celrep.2021.110236.","journal-title":"Cell Rep"},{"issue":"14","key":"779_CR96","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1158\/1078-0432.CCR-18-4046","volume":"25","author":"YZ Mazzu","year":"2019","unstructured":"Mazzu YZ, Armenia J, Chakraborty G, Yoshikawa Y, Coggins SA, Nandakumar S, et al. A novel mechanism driving poor-prognosis prostate cancer: overexpression of the DNA repair gene, ribonucleotide reductase small subunit M2 (RRM2). Clin Cancer Res. 2019;25(14):4480\u201392. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-4046.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"779_CR97","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1158\/1541-7786.MCR-19-0585","volume":"18","author":"SL Koppenhafer","year":"2020","unstructured":"Koppenhafer SL, Goss KL, Terry WW, Gordon DJ. Inhibition of the ATR\u2013CHK1 pathway in Ewing Sarcoma cells causes DNA damage and apoptosis via the CDK2-mediated degradation of RRM2. Mol Cancer Res. 2020;18(1):91\u2013104. https:\/\/doi.org\/10.1158\/1541-7786.MCR-19-0585.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"779_CR98","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48076-9","volume":"15","author":"CB Prasad","year":"2024","unstructured":"Prasad CB, Oo A, Liu Y, Qiu Z, Zhong Y, Li N, et al. The thioredoxin system determines CHK1 inhibitor sensitivity via redox-mediated regulation of ribonucleotide reductase activity. Nat Commun. 2024;15(1):4667. https:\/\/doi.org\/10.1038\/s41467-024-48076-9.","journal-title":"Nat Commun"},{"key":"779_CR99","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.phrs.2016.10.027","volume":"114","author":"BE Kennedy","year":"2016","unstructured":"Kennedy BE, Sharif T, Martell E, Dai C, Kim Y, Lee PWK, et al. NAD+ salvage pathway in cancer metabolism and therapy. Pharmacol Res. 2016;114:274\u201383. https:\/\/doi.org\/10.1016\/j.phrs.2016.10.027.","journal-title":"Pharmacol Res"},{"issue":"23","key":"779_CR100","doi-asserted-by":"publisher","first-page":"7301","DOI":"10.1158\/1078-0432.CCR-17-1121","volume":"23","author":"CM Heske","year":"2017","unstructured":"Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, et al. Matrix screen identifies synergistic combination of PARP inhibitors and nicotinamide phosphoribosyltransferase (NAMPT) inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017;23(23):7301\u201311. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1121.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"779_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-30081-5","volume":"13","author":"SA Sauriol","year":"2023","unstructured":"Sauriol SA, Carmona E, Udaskin ML, Radulovich N, Leclerc-Desaulniers K, Rottapel R, et al. Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer. Sci Rep. 2023;13(1):3334. https:\/\/doi.org\/10.1038\/s41598-023-30081-5.","journal-title":"Sci Rep"},{"issue":"1","key":"779_CR102","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/mutage\/gez019","volume":"35","author":"AR Kaplan","year":"2020","unstructured":"Kaplan AR, Glazer PM. Impact of hypoxia on DNA repair and genome integrity. Mutagenesis. 2020;35(1):61\u20138. https:\/\/doi.org\/10.1093\/mutage\/gez019.","journal-title":"Mutagenesis"},{"issue":"8","key":"779_CR103","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1038\/s42255-023-00863-2","volume":"5","author":"T TeSlaa","year":"2023","unstructured":"TeSlaa T, Ralser M, Fan J, Rabinowitz JD. The pentose phosphate pathway in health and disease. Nat Metab. 2023;5(8):1275\u201389. https:\/\/doi.org\/10.1038\/s42255-023-00863-2.","journal-title":"Nat Metab"},{"issue":"7","key":"779_CR104","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.molonc.2015.03.003","volume":"9","author":"MGP Van Der Wijst","year":"2015","unstructured":"Van Der Wijst MGP, Huisman C, Mposhi A, Roelfes G, Rots MG. Targeting Nrf2 in healthy and malignant ovarian epithelial cells: Protection versus promotion. Mol Oncol. 2015;9(7):1259\u201373. https:\/\/doi.org\/10.1016\/j.molonc.2015.03.003.","journal-title":"Mol Oncol"},{"issue":"9","key":"779_CR105","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10090337","volume":"10","author":"AP Nayak","year":"2018","unstructured":"Nayak AP, Kapur A, Barroilhet L, Patankar MS. Oxidative phosphorylation: a target for novel therapeutic strategies against ovarian cancer. Cancers. 2018;10(9):337. https:\/\/doi.org\/10.3390\/cancers10090337.","journal-title":"Cancers"},{"key":"779_CR106","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.971479","volume":"12","author":"Y Wu","year":"2022","unstructured":"Wu Y, Zhang X, Wang Z, Zheng W, Cao H, Shen W. Targeting oxidative phosphorylation as an approach for the treatment of ovarian cancer. Front Oncol. 2022;12:971479. https:\/\/doi.org\/10.3389\/fonc.2022.971479.","journal-title":"Front Oncol"},{"issue":"19","key":"779_CR107","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910557","volume":"22","author":"P Gralewska","year":"2021","unstructured":"Gralewska P, Gajek A, Marczak A, Rogalska A. Metformin affects Olaparib sensitivity through induction of apoptosis in epithelial ovarian cancer cell lines. Int J Mol Sci. 2021;22(19):10557. https:\/\/doi.org\/10.3390\/ijms221910557.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"779_CR108","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1158\/0008-5472.CAN-21-1223","volume":"82","author":"C Ghilardi","year":"2022","unstructured":"Ghilardi C, Moreira-Barbosa C, Brunelli L, Ostano P, Panini N, Lupi M, et al. PGC1\u03b1\/\u03b2 expression predicts therapeutic response to oxidative phosphorylation inhibition in Ovarian Cancer. Cancer Res. 2022;82(7):1423\u201334. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-1223.","journal-title":"Cancer Res"},{"issue":"6","key":"779_CR109","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/jnci\/djy160","volume":"111","author":"HQ Ju","year":"2019","unstructured":"Ju HQ, Lu YX, Chen DL, Zuo ZX, Liu ZX, Wu QN, et al. Modulation of redox homeostasis by inhibition of MTHFD2 in colorectal cancer: mechanisms and therapeutic implications. JNCI. 2019;111(6):584\u201396. https:\/\/doi.org\/10.1093\/jnci\/djy160.","journal-title":"JNCI"},{"issue":"1","key":"779_CR110","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-025-03447-y","volume":"44","author":"C Mancini","year":"2025","unstructured":"Mancini C, Lori G, Mattei G, Iozzo M, Desideri D, Cianchi F, et al. PHGDH drives 5-FU chemoresistance in colorectal cancer through the Hedgehog signaling. J Exp Clin Cancer Res. 2025;44(1):198. https:\/\/doi.org\/10.1186\/s13046-025-03447-y.","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"779_CR111","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s43018-022-00331-y","volume":"3","author":"N Bonagas","year":"2022","unstructured":"Bonagas N, Gustafsson NMS, Henriksson M, Marttila P, Gustafsson R, Wiita E, et al. Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress. Nat Cancer. 2022;3(2):156\u201372. https:\/\/doi.org\/10.1038\/s43018-022-00331-y.","journal-title":"Nat Cancer"},{"issue":"1","key":"779_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2025.101817","volume":"13","author":"S Josephraj","year":"2026","unstructured":"Josephraj S, Wang CJ, Cui Q, Dong Z, Liu JY, Zhang JT. Targeting fatty acid synthase to overcome PARP inhibitor resistance and to create an artificial synthetic lethality for triple-negative breast cancer. Genes Dis. 2026;13(1):101817. https:\/\/doi.org\/10.1016\/j.gendis.2025.101817.","journal-title":"Genes Dis"},{"issue":"1","key":"779_CR113","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s43018-020-00148-7","volume":"2","author":"AK Mehta","year":"2020","unstructured":"Mehta AK, Cheney EM, Hartl CA, Pantelidou C, Oliwa M, Castrillon JA, et al. Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. Nat Cancer. 2020;2(1):66\u201382. https:\/\/doi.org\/10.1038\/s43018-020-00148-7.","journal-title":"Nat Cancer"},{"issue":"1","key":"779_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-020-00311-0","volume":"6","author":"K Begg","year":"2020","unstructured":"Begg K, Tavassoli M. Inside the hypoxic tumour: reprogramming of the DDR and radioresistance. Cell Death Discov. 2020;6(1):77. https:\/\/doi.org\/10.1038\/s41420-020-00311-0.","journal-title":"Cell Death Discov"},{"issue":"2","key":"779_CR115","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15(2):81\u201394. https:\/\/doi.org\/10.1038\/nrclinonc.2017.166.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"779_CR116","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00109-020-01874-2","volume":"98","author":"S Ram\u00f3n Y Cajal","year":"2020","unstructured":"Ram\u00f3n Y Cajal S, Ses\u00e9 M, Capdevila C, Aasen T, De Mattos-Arruda L, Diaz-Cano SJ, et al. Clinical implications of intratumor heterogeneity: challenges and opportunities. J Mol Med. 2020;98(2):161\u201377. https:\/\/doi.org\/10.1007\/s00109-020-01874-2.","journal-title":"J Mol Med"},{"key":"779_CR117","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.24803.1","volume":"9","author":"S Shen","year":"2020","unstructured":"Shen S, Clairambault J. Cell plasticity in cancer cell populations. F1000Res. 2020;9:635. https:\/\/doi.org\/10.12688\/f1000research.24803.1.","journal-title":"F1000Res"},{"issue":"1","key":"779_CR118","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01891-4","volume":"9","author":"J He","year":"2024","unstructured":"He J, Qiu Z, Fan J, Xie X, Sheng Q, Sui X. Drug tolerant persister cell plasticity in cancer: a revolutionary strategy for more effective anticancer therapies. Signal Transduct Target Ther. 2024;9(1):209. https:\/\/doi.org\/10.1038\/s41392-024-01891-4.","journal-title":"Signal Transduct Target Ther"},{"issue":"17","key":"779_CR119","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.1158\/1078-0432.CCR-24-0545","volume":"30","author":"J Cui","year":"2024","unstructured":"Cui J, Li X, Deng S, Du C, Fan H, Yan W, et al. Identification of therapy-induced clonal evolution and resistance pathways in minimal residual clones in multiple myeloma through single-cell sequencing. Clin Cancer Res. 2024;30(17):3919\u201336. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-0545.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"779_CR120","doi-asserted-by":"publisher","DOI":"10.3390\/cimb47090730","volume":"47","author":"S Pattabiram","year":"2025","unstructured":"Pattabiram S, Gangadaran P, Dhayalan S, Chatterjee G, Reyaz D, Prakash K, et al. Decoding the tumor microenvironment: insights and new targets from single-cell sequencing and spatial transcriptomics. Curr Issues Mol Biol. 2025;47(9):730. https:\/\/doi.org\/10.3390\/cimb47090730.","journal-title":"Curr Issues Mol Biol"},{"issue":"3","key":"779_CR121","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE De Visser","year":"2023","unstructured":"De Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41(3):374\u2013403. https:\/\/doi.org\/10.1016\/j.ccell.2023.02.016.","journal-title":"Cancer Cell"},{"issue":"1","key":"779_CR122","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/cpt.1211","volume":"106","author":"IH Bartelink","year":"2019","unstructured":"Bartelink IH, Jones EF, Shahidi\u2010Latham SK, Lee PRE, Zheng Y, Vicini P, et al. Tumor drug penetration measurements could be the neglected piece of the personalized cancer treatment puzzle. Clin Pharmacol Ther. 2019;106(1):148\u201363. https:\/\/doi.org\/10.1002\/cpt.1211.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"779_CR123","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01332-8","volume":"8","author":"Z Chen","year":"2023","unstructured":"Chen Z, Han F, Du Y, Shi H, Zhou W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023;8(1):70. https:\/\/doi.org\/10.1038\/s41392-023-01332-8.","journal-title":"Signal Transduct Target Ther"},{"key":"779_CR124","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.626229","volume":"9","author":"M Tang","year":"2021","unstructured":"Tang M, Bolderson E, O\u2019Byrne KJ, Richard DJ. Tumor hypoxia drives genomic instability. Front Cell Dev Biol. 2021;9:626229. https:\/\/doi.org\/10.3389\/fcell.2021.626229.","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"779_CR125","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1042\/BCJ20220008","volume":"479","author":"M Batie","year":"2022","unstructured":"Batie M, Frost J, Shakir D, Rocha S. Regulation of chromatin accessibility by hypoxia and HIF. Biochem J. 2022;479(6):767\u201386. https:\/\/doi.org\/10.1042\/BCJ20220008.","journal-title":"Biochem J"},{"issue":"6432","key":"779_CR126","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1126\/science.aau5870","volume":"363","author":"M Batie","year":"2019","unstructured":"Batie M, Frost J, Frost M, Wilson JW, Schofield P, Rocha S. Hypoxia induces rapid changes to histone methylation and reprograms chromatin. Science. 2019;363(6432):1222\u20136. https:\/\/doi.org\/10.1126\/science.aau5870.","journal-title":"Science"},{"issue":"3","key":"779_CR127","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030399","volume":"13","author":"G Gentric","year":"2021","unstructured":"Gentric G, Mechta-Grigoriou F. Tumor cells and cancer-associated fibroblasts: an updated metabolic perspective. Cancers. 2021;13(3):399. https:\/\/doi.org\/10.3390\/cancers13030399.","journal-title":"Cancers"},{"issue":"3","key":"779_CR128","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1004142","volume":"11","author":"F Fu","year":"2015","unstructured":"Fu F, Nowak MA, Bonhoeffer S. Spatial heterogeneity in drug concentrations can facilitate the emergence of resistance to cancer therapy. PLoS Comput Biol. 2015;11(3):e1004142. https:\/\/doi.org\/10.1371\/journal.pcbi.1004142.","journal-title":"PLoS Comput Biol"},{"issue":"5","key":"779_CR129","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1084\/jem.20180139","volume":"215","author":"T Li","year":"2018","unstructured":"Li T, Chen ZJ. The cGAS\u2013cGAMP\u2013STING pathway connects DNA damage to inflammation, senescence, and cancer. J Exp Med. 2018;215(5):1287\u201399. https:\/\/doi.org\/10.1084\/jem.20180139.","journal-title":"J Exp Med"},{"issue":"7668","key":"779_CR130","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nature23449","volume":"548","author":"KJ Mackenzie","year":"2017","unstructured":"Mackenzie KJ, Carroll P, Martin CA, Murina O, Fluteau A, Simpson DJ, et al. cGAS surveillance of micronuclei links genome instability to innate immunity. Nature. 2017;548(7668):461\u20135. https:\/\/doi.org\/10.1038\/nature23449.","journal-title":"Nature"},{"issue":"16","key":"779_CR131","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1080\/15384101.2019.1638192","volume":"18","author":"F Talens","year":"2019","unstructured":"Talens F, Van Vugt MATM. Inflammatory signaling in genomically instable cancers. Cell Cycle. 2019;18(16):1830\u201348. https:\/\/doi.org\/10.1080\/15384101.2019.1638192.","journal-title":"Cell Cycle"},{"issue":"1","key":"779_CR132","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00916-z","volume":"13","author":"M Jiang","year":"2020","unstructured":"Jiang M, Chen P, Wang L, Li W, Chen B, Liu Y, et al. cGAS-STING, an important pathway in cancer immunotherapy. J Hematol Oncol. 2020;13(1):81. https:\/\/doi.org\/10.1186\/s13045-020-00916-z.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"779_CR133","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adr7934","volume":"11","author":"C Fusco","year":"2025","unstructured":"Fusco C, Di Rella F, Liotti A, Colamatteo A, Ferrara AL, Gigantino V, et al. CD4+ FOXP3Exon2+ regulatory T cell frequency predicts breast cancer prognosis and survival. Sci Adv. 2025;11(3):eadr7934. https:\/\/doi.org\/10.1126\/sciadv.adr7934.","journal-title":"Sci Adv"},{"issue":"4","key":"779_CR134","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41584-022-00905-1","volume":"19","author":"A Pezone","year":"2023","unstructured":"Pezone A, Olivieri F, Napoli MV, Procopio A, Avvedimento EV, Gabrielli A. Inflammation and DNA damage: cause, effect or both. Nat Rev Rheumatol. 2023;19(4):200\u201311. https:\/\/doi.org\/10.1038\/s41584-022-00905-1.","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"779_CR135","doi-asserted-by":"publisher","DOI":"10.3390\/biology9120485","volume":"9","author":"L Cuollo","year":"2020","unstructured":"Cuollo L, Antonangeli F, Santoni A, Soriani A. The senescence-associated secretory phenotype (SASP) in the challenging future of cancer therapy and age-related diseases. Biology. 2020;9(12):485. https:\/\/doi.org\/10.3390\/biology9120485.","journal-title":"Biology"},{"issue":"15","key":"779_CR136","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1158\/0008-5472.CAN-19-0761","volume":"79","author":"Q Zhang","year":"2019","unstructured":"Zhang Q, Green MD, Lang X, Lazarus J, Parsels JD, Wei S, et al. Inhibition of ATM increases interferon signaling and sensitizes pancreatic cancer to immune checkpoint blockade therapy. Cancer Res. 2019;79(15):3940\u201351. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-0761.","journal-title":"Cancer Res"},{"issue":"3","key":"779_CR137","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-022-04219-z","volume":"79","author":"R Yu","year":"2022","unstructured":"Yu R, Zhu B, Chen D. Type I interferon-mediated tumor immunity and its role in immunotherapy. Cell Mol Life Sci. 2022;79(3):191. https:\/\/doi.org\/10.1007\/s00018-022-04219-z.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"779_CR138","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03555-8","volume":"9","author":"A Takahashi","year":"2018","unstructured":"Takahashi A, Loo TM, Okada R, Kamachi F, Watanabe Y, Wakita M, et al. Downregulation of cytoplasmic DNases is implicated in cytoplasmic DNA accumulation and SASP in senescent cells. Nat Commun. 2018;9(1):1249. https:\/\/doi.org\/10.1038\/s41467-018-03555-8.","journal-title":"Nat Commun"},{"issue":"6","key":"779_CR139","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s41416-023-02326-7","volume":"129","author":"D Bhamidipati","year":"2023","unstructured":"Bhamidipati D, Haro-Silerio JI, Yap TA, Ngoi N. PARP inhibitors: enhancing efficacy through rational combinations. Br J Cancer. 2023;129(6):904\u201316. https:\/\/doi.org\/10.1038\/s41416-023-02326-7.","journal-title":"Br J Cancer"},{"issue":"4","key":"779_CR140","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/s41416-021-01406-w","volume":"125","author":"GI Shapiro","year":"2021","unstructured":"Shapiro GI, Wesolowski R, Devoe C, Lord S, Pollard J, Hendriks BS, et al. Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours. Br J Cancer. 2021;125(4):520\u20137. https:\/\/doi.org\/10.1038\/s41416-021-01406-w.","journal-title":"Br J Cancer"},{"issue":"27","key":"779_CR141","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1200\/JCO.19.02404","volume":"38","author":"TA Yap","year":"2020","unstructured":"Yap TA, O\u2019Carrigan B, Penney MS, Lim JS, Brown JS, De Miguel Luken MJ, et al. Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors. J Clin Oncol. 2020;38(27):3195\u2013204. https:\/\/doi.org\/10.1200\/JCO.19.02404.","journal-title":"J Clin Oncol"},{"key":"779_CR142","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ygyno.2023.05.063","volume":"174","author":"A Embaby","year":"2023","unstructured":"Embaby A, Kutzera J, Geenen JJ, Pluim D, Hofland I, Sanders J, et al. WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: a biomarker-enriched phase II study. Gynecol Oncol. 2023;174:239\u201346. https:\/\/doi.org\/10.1016\/j.ygyno.2023.05.063.","journal-title":"Gynecol Oncol"},{"key":"779_CR143","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1200\/PO.20.00439","volume":"5","author":"H Mahdi","year":"2021","unstructured":"Mahdi H, Hafez N, Doroshow D, Sohal D, Keedy V, Do KT, et al. Ceralasertib-mediated ATR inhibition combined with Olaparib in advanced cancers harboring DNA damage response and repair alterations (Olaparib combinations). JCO Precis Oncol. 2021;5:1432\u201342. https:\/\/doi.org\/10.1200\/PO.20.00439.","journal-title":"JCO Precis Oncol"},{"issue":"11","key":"779_CR144","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1016\/j.celrep.2018.11.054","volume":"25","author":"L Ding","year":"2018","unstructured":"Ding L, Kim HJ, Wang Q, Kearns M, Jiang T, Ohlson CE, et al. PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer. Cell Rep. 2018;25(11):2972-2980.e5. https:\/\/doi.org\/10.1016\/j.celrep.2018.11.054.","journal-title":"Cell Rep"},{"issue":"1","key":"779_CR145","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.5228","volume":"9","author":"TA Yap","year":"2023","unstructured":"Yap TA, Bardia A, Dvorkin M, Galsky MD, Beck JT, Wise DR, et al. Avelumab plus Talazoparib in patients with advanced solid tumors: the JAVELIN PARP Medley nonrandomized controlled trial. JAMA Oncol. 2023;9(1):40. https:\/\/doi.org\/10.1001\/jamaoncol.2022.5228.","journal-title":"JAMA Oncol"},{"issue":"8","key":"779_CR146","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1029","volume":"5","author":"S Vinayak","year":"2019","unstructured":"Vinayak S, Tolaney SM, Schwartzberg L, Mita M, McCann G, Tan AR, et al. Open-label clinical trial of Niraparib combined with Pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 2019;5(8):1132. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1029.","journal-title":"JAMA Oncol"},{"issue":"9","key":"779_CR147","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.2181","volume":"8","author":"PA Konstantinopoulos","year":"2022","unstructured":"Konstantinopoulos PA, Gockley AA, Xiong N, Krasner C, Horowitz N, Campos S, et al. Evaluation of treatment with Talazoparib and Avelumab in patients with recurrent mismatch repair proficient endometrial cancer. JAMA Oncol. 2022;8(9):1317. https:\/\/doi.org\/10.1001\/jamaoncol.2022.2181.","journal-title":"JAMA Oncol"},{"issue":"16","key":"779_CR148","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.1158\/1078-0432.CCR-20-0056","volume":"26","author":"EJ Lampert","year":"2020","unstructured":"Lampert EJ, Zimmer A, Padget M, Cimino-Mathews A, Nair JR, Liu Y, et al. Combination of PARP inhibitor Olaparib, and PD-L1 inhibitor Durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study. Clin Cancer Res. 2020;26(16):4268\u201379. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0056.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"779_CR149","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1158\/1078-0432.CCR-23-2513","volume":"30","author":"TJ Tan","year":"2024","unstructured":"Tan TJ, Sammons S, Im YH, She L, Mundy K, Bigelow R, et al. Phase II DORA study of Olaparib with or without Durvalumab as a chemotherapy-free maintenance strategy in platinum-pretreated advanced triple-negative breast cancer. Clin Cancer Res. 2024;30(7):1240\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2513.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"779_CR150","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.5218","volume":"9","author":"AM Schram","year":"2023","unstructured":"Schram AM, Colombo N, Arrowsmith E, Narayan V, Yonemori K, Scambia G, et al. Avelumab plus Talazoparib in patients with BRCA1\/2- or ATM-altered advanced solid tumors: results from JAVELIN BRCA\/ATM, an open-label, multicenter, phase 2b, tumor-agnostic trial. JAMA Oncol. 2023;9(1):29. https:\/\/doi.org\/10.1001\/jamaoncol.2022.5218.","journal-title":"JAMA Oncol"},{"issue":"1","key":"779_CR151","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-62249-0","volume":"16","author":"MT Dillon","year":"2025","unstructured":"Dillon MT, Patin EC, Mohammed K, Guevara J, Smith SA, Dean E, et al. Tumor control and immune activation through palliative irradiation and ATR inhibition, PATRIOT Part C: a phase Ib trial. Nat Commun. 2025;16(1):7064. https:\/\/doi.org\/10.1038\/s41467-025-62249-0.","journal-title":"Nat Commun"},{"issue":"6","key":"779_CR152","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s11523-024-01102-8","volume":"19","author":"EP Hamilton","year":"2024","unstructured":"Hamilton EP, Falchook GS, Wang JS, Fu S, Oza AM, Imedio ER, et al. Adavosertib in combination with Olaparib in patients with refractory solid tumors: an open-label, dose-finding, and dose-expansion phase Ib trial. Target Oncol. 2024;19(6):879\u201392. https:\/\/doi.org\/10.1007\/s11523-024-01102-8.","journal-title":"Target Oncol"},{"issue":"4","key":"779_CR153","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s10637-019-00873-6","volume":"38","author":"JC Bendell","year":"2020","unstructured":"Bendell JC, Bischoff HG, Hwang J, Reinhardt HC, Zander T, Wang X, et al. A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer. Invest New Drugs. 2020;38(4):1145\u201355. https:\/\/doi.org\/10.1007\/s10637-019-00873-6.","journal-title":"Invest New Drugs"},{"issue":"4","key":"779_CR154","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1158\/1078-0432.CCR-20-3089","volume":"27","author":"TE Keenan","year":"2021","unstructured":"Keenan TE, Li T, Vallius T, Guerriero JL, Tayob N, Kochupurakkal B, et al. Clinical efficacy and molecular response correlates of the WEE1 inhibitor Adavosertib combined with Cisplatin in patients with metastatic triple-negative breast cancer. Clin Cancer Res. 2021;27(4):983\u201391. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3089.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"779_CR155","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1136\/ijgc-2023-004491","volume":"33","author":"E Gonzalez-Ochoa","year":"2023","unstructured":"Gonzalez-Ochoa E, Milosevic M, Corr B, Abbruzzese JL, Girda E, Miller RW, et al. A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers. Int J Gynecol Cancer. 2023;33(8):1208\u201314. https:\/\/doi.org\/10.1136\/ijgc-2023-004491.","journal-title":"Int J Gynecol Cancer"},{"issue":"20","key":"779_CR156","doi-asserted-by":"publisher","first-page":"4514","DOI":"10.1158\/0008-5472.CAN-19-3971","volume":"80","author":"YA Shen","year":"2020","unstructured":"Shen YA, Hong J, Asaka R, Asaka S, Hsu FC, Suryo Rahmanto Y, et al. Inhibition of the MYC-regulated glutaminase metabolic axis is an effective synthetic lethal approach for treating chemoresistant ovarian cancers. Cancer Res. 2020;80(20):4514\u201326. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-3971.","journal-title":"Cancer Res"},{"issue":"2","key":"779_CR157","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.ygyno.2016.06.005","volume":"142","author":"M Hijaz","year":"2016","unstructured":"Hijaz M, Chhina J, Mert I, Taylor M, Dar S, Al-Wahab Z, et al. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer. Gynecol Oncol. 2016;142(2):323\u201331. https:\/\/doi.org\/10.1016\/j.ygyno.2016.06.005.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"779_CR158","doi-asserted-by":"publisher","DOI":"10.1186\/s40170-023-00320-4","volume":"11","author":"C Terlizzi","year":"2023","unstructured":"Terlizzi C, De Rosa V, Iommelli F, Pezone A, Altobelli GG, Maddalena M, et al. ATM inhibition blocks glucose metabolism and amplifies the sensitivity of resistant lung cancer cell lines to oncogene driver inhibitors. Cancer Metab. 2023;11(1):20. https:\/\/doi.org\/10.1186\/s40170-023-00320-4.","journal-title":"Cancer Metab"},{"issue":"1","key":"779_CR159","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-018-0810-7","volume":"37","author":"L Yin","year":"2018","unstructured":"Yin L, Liu Y, Peng Y, Peng Y, Yu X, Gao Y, et al. PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1\/BRCA1 DNA damage repair complex in prostate cancer cells. J Exp Clin Cancer Res. 2018;37(1):153. https:\/\/doi.org\/10.1186\/s13046-018-0810-7.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"779_CR160","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-024-01954-y","volume":"27","author":"R Pacaud","year":"2025","unstructured":"Pacaud R, Thomas S, Chaudhuri S, Lazar A, Timmerman LA, Munster PN. Low dose DNA methyltransferase inhibitors potentiate PARP inhibitors in homologous recombination repair deficient tumors. Breast Cancer Res. 2025;27(1):8. https:\/\/doi.org\/10.1186\/s13058-024-01954-y.","journal-title":"Breast Cancer Res"},{"issue":"17","key":"779_CR161","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1158\/1078-0432.CCR-22-3897","volume":"29","author":"L Ramos","year":"2023","unstructured":"Ramos L, Truong S, Zhai B, Joshi J, Ghaidi F, Lizardo MM, et al. A bifunctional PARP-HDAC inhibitor with activity in Ewing Sarcoma. Clin Cancer Res. 2023;29(17):3541\u201353. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3897.","journal-title":"Clin Cancer Res"},{"issue":"23","key":"779_CR162","doi-asserted-by":"publisher","first-page":"5651","DOI":"10.1158\/1078-0432.CCR-16-0247","volume":"22","author":"EH Stover","year":"2016","unstructured":"Stover EH, Konstantinopoulos PA, Matulonis UA, Swisher EM. Biomarkers of response and resistance to DNA repair targeted therapies. Clin Cancer Res. 2016;22(23):5651\u201360. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0247.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"779_CR163","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01105-2","volume":"14","author":"Y Lei","year":"2021","unstructured":"Lei Y, Tang R, Xu J, Wang W, Zhang B, Liu J, et al. Applications of single-cell sequencing in cancer research: progress and perspectives. J Hematol Oncol. 2021;14(1):91. https:\/\/doi.org\/10.1186\/s13045-021-01105-2.","journal-title":"J Hematol Oncol"},{"issue":"25","key":"779_CR164","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391\u2013402. https:\/\/doi.org\/10.1056\/NEJMoa1910962.","journal-title":"N Engl J Med"},{"issue":"25","key":"779_CR165","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, P\u00e9rol D, Gonz\u00e1lez-Mart\u00edn A, Berger R, et al. Olaparib plus Bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1911361.","journal-title":"N Engl J Med"},{"issue":"26","key":"779_CR166","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495\u2013505. https:\/\/doi.org\/10.1056\/NEJMoa1810858.","journal-title":"N Engl J Med"},{"issue":"25","key":"779_CR167","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al. Adjuvant Olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384(25):2394\u2013405. https:\/\/doi.org\/10.1056\/NEJMoa2105215.","journal-title":"N Engl J Med"},{"issue":"4","key":"779_CR168","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance Olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1903387.","journal-title":"N Engl J Med"},{"issue":"22","key":"779_CR169","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J De Bono","year":"2020","unstructured":"De Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091\u2013102. https:\/\/doi.org\/10.1056\/NEJMoa1911440.","journal-title":"N Engl J Med"},{"issue":"4","key":"779_CR170","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.eururo.2020.09.024","volume":"79","author":"KH Stopsack","year":"2021","unstructured":"Stopsack KH. Efficacy of PARP inhibition in metastatic castration-resistant prostate cancer is very different with non-BRCA DNA repair alterations: Reconstructing prespecified endpoints for cohort B from the phase 3 PROfound trial of Olaparib. Eur Urol. 2021;79(4):442\u20135. https:\/\/doi.org\/10.1016\/j.eururo.2020.09.024.","journal-title":"Eur Urol"},{"issue":"34","key":"779_CR171","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1200\/JCO.22.01003","volume":"40","author":"BJ Monk","year":"2022","unstructured":"Monk BJ, Parkinson C, Lim MC, O\u2019Malley DM, Oaknin A, Wilson MK, et al. A randomized, Phase III trial to evaluate Rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA\u2013MONO\/GOG-3020\/ENGOT-ov45). J Clin Oncol. 2022;40(34):3952\u201364. https:\/\/doi.org\/10.1200\/JCO.22.01003.","journal-title":"J Clin Oncol"},{"issue":"12","key":"779_CR172","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201809172","volume":"10","author":"M Castroviejo\u2010Bermejo","year":"2018","unstructured":"Castroviejo\u2010Bermejo M, Cruz C, Llop\u2010Guevara A, Guti\u00e9rrez\u2010Enr\u00edquez S, Ducy M, Ibrahim YH, et al. A RAD 51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. EMBO Mol Med. 2018;10(12):e9172. https:\/\/doi.org\/10.15252\/emmm.201809172.","journal-title":"EMBO Mol Med"},{"issue":"13","key":"779_CR173","doi-asserted-by":"publisher","DOI":"10.1172\/JCI189511","volume":"135","author":"A Schab","year":"2025","unstructured":"Schab A, Compadre A, Drexler R, Loeb M, Rodriguez K, Brill J, et al. Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination\u2013proficient ovarian cancer. J Clin Invest. 2025;135(13):e189511. https:\/\/doi.org\/10.1172\/JCI189511.","journal-title":"J Clin Invest"},{"issue":"12","key":"779_CR174","doi-asserted-by":"publisher","DOI":"10.3390\/genes14122205","volume":"14","author":"S Liu","year":"2023","unstructured":"Liu S, Byrne BM, Byrne TN, Oakley GG. Role of RPA phosphorylation in the ATR-dependent G2 cell cycle checkpoint. Genes. 2023;14(12):2205. https:\/\/doi.org\/10.3390\/genes14122205.","journal-title":"Genes"},{"issue":"4","key":"779_CR175","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.annonc.2024.01.003","volume":"35","author":"E Harvey-Jones","year":"2024","unstructured":"Harvey-Jones E, Raghunandan M, Robbez-Masson L, Magraner-Pardo L, Alaguthurai T, Yablonovitch A, et al. Longitudinal profiling identifies co-occurring BRCA1\/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer. Ann Oncol. 2024;35(4):364\u201380. https:\/\/doi.org\/10.1016\/j.annonc.2024.01.003.","journal-title":"Ann Oncol"},{"issue":"14","key":"779_CR176","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1158\/1078-0432.CCR-22-3715","volume":"29","author":"YN Kim","year":"2023","unstructured":"Kim YN, Shim Y, Seo J, Choi Z, Lee YJ, Shin S, et al. Investigation of PARP inhibitor resistance based on serially collected circulating tumor DNA in patients with BRCA -mutated ovarian cancer. Clin Cancer Res. 2023;29(14):2725\u201334. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3715.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"779_CR177","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47271-y","volume":"15","author":"E Denisenko","year":"2024","unstructured":"Denisenko E, De Kock L, Tan A, Beasley AB, Beilin M, Jones ME, et al. Spatial transcriptomics reveals discrete tumour microenvironments and autocrine loops within ovarian cancer subclones. Nat Commun. 2024;15(1):2860. https:\/\/doi.org\/10.1038\/s41467-024-47271-y.","journal-title":"Nat Commun"},{"issue":"1","key":"779_CR178","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-022-00879-y","volume":"29","author":"WC Hsieh","year":"2022","unstructured":"Hsieh WC, Budiarto BR, Wang YF, Lin CY, Gwo MC, So DK, et al. Spatial multi-omics analyses of the tumor immune microenvironment. J Biomed Sci. 2022;29(1):96. https:\/\/doi.org\/10.1186\/s12929-022-00879-y.","journal-title":"J Biomed Sci"},{"issue":"7381","key":"779_CR179","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/nature10762","volume":"481","author":"M Greaves","year":"2012","unstructured":"Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481(7381):306\u201313. https:\/\/doi.org\/10.1038\/nature10762.","journal-title":"Nature"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-026-00779-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00779-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00779-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:20:26Z","timestamp":1783646426000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40164-026-00779-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":179,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["779"],"URL":"https:\/\/doi.org\/10.1186\/s40164-026-00779-z","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"26 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This manuscript does not include details, images, or videos relating to an individual person.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}